Prolight Diagnostics

20.95 SEK

+0.96 %

Less than 1K followers

PRLD

Nordic SME

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+0.96 %

+5.81 %

-11.60 %

-10.85 %

+70.80 %

+57.85 %

+19.21 %

-87.37 %

-46.77 %

Prolight Diagnostics develops point-of-care (POC) systems. These are small mobile instruments with disposable test cards that can perform In-Vitro Diagnostic (IVD) tests from a drop of blood. The POC system can contribute to faster and more accurate diagnoses of acute conditions. The company's launch product will be a highly sensitive measurement of troponin to be able to determine and exclude heart attacks.

Market cap

252.34M SEK

Turnover

144.03K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26.2

2026

Annual report '25

26.5

2026

Interim report Q1'26

26.5

2026

General meeting '26

All

Press releases

3rd party

ShowingAll content types

Press releaseyesterday

Prolight secures third patent in Europe for Psyros™

Prolight Diagnostics

Press release12/8/2025, 8:30 AM

BioStock publishes an article describing how Prolight Diagnostics is preparing the clinical study

Prolight Diagnostics

Press release12/8/2025, 6:25 AM

BioStock: Prolight's CTO focuses on CRO partner MDx

Prolight Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/5/2025, 10:00 AM

THE NOMINATION COMMITTEE APPOINTED FOR THE ANNUAL GENERAL MEETING 2026

Prolight Diagnostics

Regulatory press release12/4/2025, 9:00 AM

Prolight announces timetable for share reverse split

Prolight Diagnostics

Regulatory press release11/27/2025, 7:00 AM

Prolight Diagnostics publishes quarterly report Q3, 2025

Prolight Diagnostics

Regulatory press release11/19/2025, 1:45 PM

Extraordinary general meeting of Prolight Diagnostics AB (publ) on 19 November 2025

Prolight Diagnostics

Press release11/17/2025, 11:40 AM

BioStock publishes article about Prolight Diagnostics continued preparations to bring the Psyros platform to market

Prolight Diagnostics

Press release11/17/2025, 10:26 AM

BioStock: Final adjustments and validation take center stage at Prolight Diagnostics

Prolight Diagnostics

Press release11/5/2025, 1:55 PM

Prolight Diagnostics publishes investor letter for November 2025

Prolight Diagnostics

Regulatory press release10/17/2025, 10:00 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

Prolight Diagnostics

Press release8/29/2025, 11:40 AM

Emergers publishes updated analysis for Prolight Diagnostics

Prolight Diagnostics

Third party research8/29/2025, 6:18 AM

Prolight: Financing and partner interest strengthen case ahead of regulatory study - Emergers

In Q2, Prolight reported initial positive data from its ongoing whole blood study at St Thomas’ Hospital in London, showing equivalence between whole blood and plasma and thereby confirming the robust clinical performance of the PsyrosTM POC platform...

Prolight Diagnostics

Press release8/29/2025, 6:00 AM

Emergers: Equity Research | PROLIGHT: Financing and partner interest strengthen case ahead of regulatory study

Prolight Diagnostics

Regulatory press release8/28/2025, 6:00 AM

Prolight Diagnostics publishes half-year report, 2025

Prolight Diagnostics

Press release8/27/2025, 6:00 AM

Prolight receives Notice of Intention to Grant in Europe for third Psyros™ patent

Prolight Diagnostics

Press release8/1/2025, 9:00 AM

Prolight Diagnostics publishes investor letter for August 2025

Prolight Diagnostics

Press release7/21/2025, 6:00 AM

Prolight secures patent in Japan for Psyros™ technology

Prolight Diagnostics

Regulatory press release7/15/2025, 12:00 PM

Last day of trading in BTAs – conversion of BTAs into shares

Prolight Diagnostics

Third party research7/3/2025, 7:19 AM

Prolight: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships - Emergers

Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk and securing the capital needed to finalise the development, verification and pilot production of the PsyrosTM system. The broad participation from the...

Prolight Diagnostics

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.